Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Oct 20, 2021- Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent- GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent- Global COVID-19 testing-related sales were $1.9 billion in the third quarter- Excluding COVID-19 testing-related sales, third-quarter sales grew 11.7 percent on both a reported and organic basis compared to sales in 2019- Continues to strengthen portfolio with several new product approvals- Oct 18, 2021- Abbott becomes Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation- Partnership will include support of the first men's and women's and Academy football teams as well as support of the Real Madrid Foundation- Foundation supports 65,000 children per year across 80 countries through education in sportsmanship, teamwork, respect, and health and nutrition- Partnership supports Abbott's commitment to address global malnutrition over the next decade
- Sep 30, 2021- Abbott is investing $45 million annually to help identify, treat and prevent malnutrition- Innovation hub will focus on reducing malnutrition for the most vulnerable populations in the world
-
Sep 29, 2021- Talisman system builds on the minimally invasive Amplatzer PFO Occluder, the world's leading patent foramen ovale (PFO) closure device that has been used to treat more than 180,000 patients worldwide- Abbott’s PFO closure technology helps to prevent blood clots from passing from the right to left side of the heart from where they can travel to the brain and cause a stroke- The Talisman system offers the industry's widest range of device sizes in the U.S. and the occluder comes pre-attached to the delivery cable, making the device easier for physicians to use